Items Tagged ‘jak1’

February 17th, 2015

Phase III Trial Finds Jakafi Superior to Standard Therapy for Polycythemia Vera


A Phase III trial finds that Jakafi® (ruxolitinib) is more effective than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these disorders, […]

View full entry

Tags: hydrea, hydroxyurea, jak1, JAK2, jakafi, mpn, Myeloproliferative Neoplasms MPN, myeloproliferative neoplastms, News, polycythemia vera, PV, PV treatment